Business Wire

CA-VECTARA

Share
Vectara Launches Factual Consistency Score Powered by Upgraded Hughes Hallucination Evaluation Model to Enhance Transparency in GenAI Responses

Vectara, the trusted Generative AI product platform, announced the inclusion of a Factual Consistency Score (FCS) for all generative responses based on an evolved version of the groundbreaking Hughes Hallucination Evaluation Model (HHEM)—the #1 hallucination detection model on Hugging Face with 100,000+ downloads since its launch last November. The associated Hallucination Leaderboard is now the industry standard for how LLMs benchmark their average factual consistency. Vectara’s end-to-end Retrieval Augmented Generation-as-a-service (RAGaaS) platform is setting a new standard as an industry-first feature for GenAI response transparency by providing real-time end-to-end RAG observability. This innovative metric provides unprecedented visibility into the factual consistency of summarized responses within Vectara’s RAGaaS platform, empowering users to set personalized thresholds for response acceptance based on a detailed accuracy score.

With average hallucination rates of LLMs on the market ranging from 3% to 16.2%, the risk of unknown inaccuracies in their response remains a major concern, preventing widespread business adoption of this powerful technology. Vectara mitigates this ambiguity for enterprises by providing a Factual Consistency Score grading the likelihood that the generated response is a hallucination or not. Only with a standardized, scientifically calculated method for grading responses can businesses responsibly introduce GenAI into business critical applications. Users have the ability to set thresholds for response acceptance based on a detailed accuracy score, giving product teams the flexibility to act on this information according to their preferences.

Vectara’s Factual Consistency Score is a groundbreaking tool in GenAI, setting a new benchmark for real-time hallucination detection and offering superior performance, affordability, and speed, thus marking a significant leap forward in trust. Its efficiency and effectiveness enable businesses to deploy GenAI into critical product use cases without being worried about exposure to liabilities that might arise from hallucinated responses.

Vectara's Factual Consistency Score equips developers with the capability to refine and enhance a wide range of applications, from internal Q&A systems to the quality of interactions with end consumers. The strength of this score lies in its calibration, making it interpretable as a direct probability—for instance, a score of 0.98 indicates a 98% probability of factual consistency. This contrasts sharply with many contemporary ML classifiers that disregard calibration, thus sacrificing clarity and direct interpretability.

"Integrating Vectara's Factual Consistency Score into the Yobi app will revolutionize how we handle AI transparency and accuracy for business use cases. By providing visibility and accountability into answers provided by our platform, we can stay true to our commitment to responsible AI that enterprises can depend on,” said Ahmed Reza, Founder and CEO of the Yobi app. “As a Co-Innovate Partner with Vectara, we're thrilled to see such advanced technology directly incorporated into the Vectara platform.”

The advanced HHEM that powers the Factual Consistency Score gives greater visibility than previously released open-sourced versions, offering enhanced accuracy and extended language support. This initiative is part of Vectara's commitment to transparency and control, empowering businesses with the autonomy to manage AI responses effectively.

"Just as we were early in pioneering RAG to enhance the relevance and quality of generated content, we are once again at the forefront of responsible AI by being completely open about our efforts to mitigate hallucinations in Generative AI," said Amr Awadallah, co-founder and CEO of Vectara. "By providing our customers with real-time access to factual consistency scores, we're not just engineering trust; we're handing over the control, enabling them to make informed decisions on how to utilize the responses generated by our RAGaaS platform."

About Vectara

Vectara is an end-to-end platform for embedding powerful generative AI features into applications with extraordinary results. As an end-to-end Retrieval Augmented Generation (RAG) platform, Vectara delivers the shortest path to a correct answer/action through a safe, secure, and trusted entry point. Vectara never trains on your data, allowing businesses to embed generative AI capabilities without the risk of data or privacy violations. To learn more, visit vectara.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240326712242/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Approximately 7% of people in the United States (U.S.) have atopic dermatitis – a common, chronic, and flaring inflammatory skin disease, characterized by persistent itch and recurrent skin lesions1-4 While currently available treatments may improve some signs and symptoms of the disease, many patients do not respond optimally to approved therapies and do not experience itch relief and clear skin to the same degree2,5-7 Nemluvio® (nemolizumab) is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31. IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and epidermal dysregulation in atopic dermatitis2,9-11 This approval follows Nemluvio’s recent approval for the treatment of adults with prurigo nodularis from the U.S. Food and Drug Administration earlier in August 202412 Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug

Andersen Global forstærker sin dækning af Asien-Stillehavsregionen med ejendomsrådgivere i Australien13.12.2024 19:39:00 CET | Pressemeddelelse

Andersen Global styrker sin platform i Asien og Stillehavsregionen gennem en samarbejdsaftale med Charter Keck Cramer, der er et af Australiens førende, uafhængige ejendomsrådgivningsfirmaer. Det, der i 1970 begyndte som en lille virksomhed, Charter Keck Cramer, har siden udviklet sig til et tværfagligt firma med mere end 170 eksperter, der er fordelt på fem kontorer i Australien og Singapore. Firmaet tilbyder et omfattende udvalg af ejendomsrelaterede ydelser, herunder værdiansættelser inden for bolig- og erhvervsejendomme, ejendoms- og udviklingsrådgivning, ejendomsdata og analyser samt strategisk planlægning og byøkonomi samt kvantitetsopmåling. Charter Keck Cramer betjener en mangfoldig australsk og international kundebase, herunder offentlige og private virksomheder, ejere og udviklere, større banker og finansielle institutioner, institutionelle ejere og truster, statslige organer og familiekontorer. "Vores vækst over de seneste 54 år er drevet af vores uafhængige, skræddersyede t

Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press release

Businesses Must Employ a Multi-Layered Approach to Fight GenAI Fraud Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unli

Capcom Announces Onimusha Way of the Sword, Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press release

Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo

BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press release

BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye